CEFPIROME. LITERATURE REVIEW

Researchers around the world acknowledge a continuing growth of antibiotic resistance. Thus, it is especially important to select from a wide range of antibacterial agents in the pharmaceutical market the ones appropriate for specific regional sensitivity, only in accordance with clearly defined indications and in order of priority for each specific case. The most frequently used are wide range drugs, including the 4^th-generation cephalosporins active against gram-positive and gram-negative microbes and most anaerobes. This review is dedicated to a representative of this group – cefpirome. The authors indicate the primary indications for use thereof and present a comparative effectiveness analysis. Cefpirome is as effective as cefepime, which is important, particularly because of growth of bacterial resistance against the 3^rd-generation cephalosporins. Its significant advantage is activity against several enterococci and anaerobes. Cefpirome penetrates various body tissues fairly well and establishes there bactericidal concentrations against most known clinically significant microbes. The trials have demonstrated clinical effectiveness of the drug for various nosocomial infections, such as sepsis (62-77%), febrile neutropenia (53-84%), intra-abdominal infections (83%), complicated urinary infections (100%) etc. The drug features low toxicity: it does not exceed the one in cefepime and the 3^rd-generation cephalosporins, which makes it possible to use cefpirome as the drug of the 1^st choice for severe hospital-acquired infections given its wide antibacterial range and clinical significance.

1. Norrby S.R.I., Geddes A.M., Shah P.M. Randomized comparative trial of cefpirome versus ceftazidime in the empirical treatment of suspected bacteraemia or sepsis. Multicentre Study Group. J Antimicrob Chemother. 1998 Oct; 42 (4): 503−9.

2. Lehrnbecher T., Robert P., Sarah A., Alvaro F., Carlesse F., Fisher B., Hakim H., Santolaya M., Castagnola E., Davis B.L., Dupuis L.L., Gibson F., Groll A.H., Gaur A., Gupta A., Kebudi R., Petrilli S., Steinbach W.J., Villarroel M., Zaoutis T., Sung L. Guideline for the Management of Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation. Journal of clinical oncology. Special article. J Clin Oncol. 30. 2012 by American Society of Clinical Oncology. Published Ahead of Print on September 17, 2012 as 10.1200/JCO.2012.42.7161. Available at: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.42.7161

3. Formulyar RONTs im. N.N. Blokhina RAMN. Antimikrobnye preparaty i standarty lecheniya infektsionnykh oslozhnenii u onkologicheskikh bol'nykh. Pod red. N.V. Dmitrievoi [N.N. Blokhin RCRC Form. Antimicrobials and Standards of Treatment of Infectious Complications in Patients with Cancer. Edited by N.V. Dmitrieva]. Moscow, Prakticheskaya meditsina, 2011. 270 p.

4. Dmitrieva N.V., Petukhova I.N., Grigor'evskaya Z.V. Vancomycin and linezolid in nosocomial infections caused by methicillin-resistant staphylococci. Vrach = The Doctor. 2012; 2: 39−43.

5. Bergeret M.I., Boutros N., Raymond J. In vitro combined bactericidal activity of cefpirome and glycopeptides against glycopeptides and oxacillin-resistant staphylococci. Int J Antimicrob Agents. 2004 Mar; 23 (3): 247−53.

6. Georges B.I., Roche C., Archambaud M., Decun J.F., Cougot P., Conil J.M., Chaminade B., Andrieu P., Saivin S., Bonnet E., Chabanon G., Houin G., Samii K., Virenque C. Importance of a cefpirome-vancomycin combination on bactericidal kinetics in severe MRSA infections in intensive care. Pathol Biol (Paris). 2002 Apr; 50 (3): 161−8.

7. Hafeez S.I., Izhar M., Ahmed A., Zafar A., Naeem M. In vitro antimicrobial activity of Cefpirome: a new fourth-generation cephalosporin against clinically significant bacteria J Pak Med Assoc. 2000 Aug; 50 (8): 250−2.

8. Poiata A., Tuchilus C., Badicut I., Buiuc D. Cefpirome susceptibility in staphylococci isolates. Cefpirome susceptibility in staphylococci isolates. Rev Med Chir Soc Med Nat Iasi. 2007; 111 (1): 276−9.

9. Ishii Y.I., Ueda C., Kouyama Y., Tateda K., Yamaguchi K. Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008). Diagn Microbiol Infect Dis. 2011 Apr; 69 (4): 443−8.

10. Strateva T.I., Ouzounova-Raykova V., Markova B., Todorova A., Marteva-Proevska Y., Mitov I. Problematic clinical isolates of Pseudomonas aeruginosa from the university hospitals in Sofia, Bulgaria: current status of antimicrobial resistance and prevailing resistance mechanisms. J Med Microbiol. 2007 Jul; 56 (Pt. 7): 956−63.

11. Ishii Y.I., Alba J., Kimura S., Shiroto K., Yamaguchi K. Evaluation of antimicrobial activity of beta-lactam antibiotics using Etest against clinical isolates from 60 medical centres in Japan. Int J Antimicrob Agents. 2005 Apr; 25 (4): 296−301.

12. Tuchiluş C.I., Poiată A., Iancu L.S., Bădicuţ I., Ambăruş A., Buiuc D. Susceptibility of Klebsiella spp. to cefpirome and cefepime. Rev Med Chir Soc Med Nat Iasi. 2006 Apr-Jun; 110 (2): 465−7.

13. Huang C.C.I., Wu C.J., Wang L.R., Lee H.C., Chang C.M., Lee N.Y., Chen T.Y., Ko W.C. Antimicrobial susceptibility of bacteremic isolates from cancer patients with or without neutropenia at a medical center in southern Taiwan. J Microbiol Immunol Infect. 2011 Oct; 44 (5): 376−81.

14. Joukhadar C.I., Klein N., Mayer B.X., Kreischitz N., Delle-Karth G., Palkovits P., Heinz G., Müller M. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med. 2002 Jul; 30 (7): 1478−82.

15. Lindenmann J.I., Kugler S.A., Matzi V., Porubsky C., Maier A., Dittrich P., Graninger W., Smolle-Jüttner F.M., Joukhadar C. High extracellular levels of cefpirome in unaffected and infected lung tissue of patients. J Antimicrob Chemother. 2011 Jan; 66 (1): 160−4.

16. Dmitrieva N.V. Febrile neutropenia in cancer patients. Russkii meditsinskii zhurnal = Russian Medical Journal. 2003; 12 (11): 734–736.

17. Bauduer F.I., Cousin T., Boulat O., Rigal-Huguet F., Molina L., Fegueux N., Jourdan E., Boiron J.M., Reiffers J. BGMT Collaborative Group. A randomized prospective multicentre trial of cefpirome versus piperacillin/tazobactam in febrile neutropenia. Leuk Lymphoma. 2001 Jul; 42 (3): 379−86.

18. Su Y.C., Sheu Y.T., Peng M.Y., Yeh K.M., Huang C.Y., Wang S.M., Chang Y.F., Chang M.C., Wu M.F., Tsao S.M. An observational study on the empiric use of cefpirome in febrile neutropenia. J Microbiol Immunol Infect. 2007; 40 (1): 62−7.

19. Timmers G.J., van Vuurden D.G., Swart E.L., Simoons-Smit A.M., Huijgens P.C. Cefpirome as empirical treatment for febrile neutropenia in patients with hematologic malignancies. Haematologica. 2005 Jul; 90 (7): 1005−6.

20. Kumamoto Y., Tsukamoto T., Matsukawa M., Kunishima Y., Hirose T., Shigeta S., Yamaguchi O., Ishibashi K., Suzutani T., Yoshida H., Imafuku Y., Murai M., Watanabe K., Kobayashi Y., Uchida H., Matsuda S., Sato S., Fujime M., Fujita K., Igari J., Oguri T., Yamaguchi K., Furuya N., Deguchi T., Ishihara S., Ooe H., Oka T, Kitamura M., Fukuhara Y., Kamidono S., Arakawa S., Kumon H., Monden K., Matsumoto T., Muratani T., Naito S., Egashira T., Konishi T., Kohno S., Hirakata Y., Kondo A., Matsuda J., Nakano M. Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). III. Secular changes in susceptibility. Japanise J Antibiot. 2006 Aug; 59 (4): 217−315.

21. Nikolovski M., Kotsev Iu., Panchev P. Treatment with cerom (cefpirom) in severe urulogical infections. Khirurgiia (Sofia). 2004; 60 (4−5): 39−41.

22. Hayashi Y., Yamashita T., Nakata T., Huji T., Kojima T, Katayama H., Ishikawa M. Cefpirome sulphate for gynecological infections and prophilaxis of non-laparatomy surgery in patients with begin disease. Int J Antimicrob Agents. 2002 May; 19 (5): 405−11.

23. Mikamo H.I., Sato Y., Hayasaki Y., Hua Y.X., Tamaya T., Iwasa S., Kawazoe K., Furuta N., Ito M., Nomura M., Tsukahara Y., Furui K., Sakakibara K., Hattori S., Sugiyama M., Ohnishi N., Hirose R., Nakagawa M., Yamada Y., Hashiyama T., Arahori K., Izumi K., Shiraki S., Morishita S., Watanabe K. Clinical efficacy of cefpirome sulfate against Bacteroides species, Prevotella species and Porphyromonas species. Society of Anaerobic Bacterial Infections in the fields of obstetrics and gynecology in Gifu. Japanise J Antibiot. 2000 Jan; 53 (1): 26−45.

24. Giamarellou H. Forth generation cephalosporins in the antimicrobial chemotherapy of surgical infections. J Chemotherapy. 1999 Dec; 11 (2): 486−93.

25. Cereda R.F.I., Sader H.S., Barth A.L., Segura A., Kage R., Novakonski A., Pignatari A.C. Evaluation of the in vitro Activity of Two Fourth ― Generation Cephalosporins Against Bacterial Samples Isolated From Patients in Several Brazilian Hospitals. Braz J Infect Dis. 1999 Oct; 3 (5): 189−196.

26. Matsuoka S., Takahashi Y., Kuroda Y. Clinica levaluation of Cefpirome in pediatric field. Japanise J Antibiot. 1991; 44 (4): 462−465.

27. Meguro H., Fujii R., Tajima T., Abe T. Clinical evaluation of Cefpirome in Children. Japanise J Antibiot.1991 Feb; 44 (2): 160−7.

28. Furakawa S., Okada T. Clinical evaluation of Cefpirome in pediatrics and a study on the penetration into cerebrospinal fluid. Japanise J Antibiot. 1991; 44 (4): 472−479.